Wockhardt announced today morning that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), United States of America (USA) is supporting a Phase 1 clinical trial of Wockhardt’s novel once-a-day, multidrug-resistant (MDR) Gram-negative targeted antibiotic WCK 6777.

The trial will be conducted at NIAID’s Phase I clinical trial units in the USA. NIAID will sponsor the investigational new drug application for the study.

The Food and Drug Administration (USA) has granted a qualified infectious disease product designation to WCK 6777, which signifies its ability to meet unmet medical need and facilitates faster approval process.

The stock opened 1% higher at Rs.291.50 and rose 3% to hit an intraday high at Rs,298. Its 52-week high and low stands at Rs.741.75 and Rs.287.05 respectively.